Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these substances increase insulin production

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing contrasts in their pha